Adherence to antiviral therapy is a significant issue for HIV-infected drug abusers. The combined studies of lenfivirus-infected rodent and rhesus macaques proposed here build upon exciting preliminary data obtained on nanoformulafions of anfiretrovirals (nanoART) and the data that will result from projects 1 and 2 (A. Kabanov and H. Gendelman). Before proceeding to nonhuman primate studies, rodent testing of nanoART in virus-infected EcoHIV and/or humanized mice. These studies will be conducted with D. Volsky and L. Poluektova. Thus, we will begin in Aim 1 performing rodent biodistribufion (including bioimaging) and pharmacokinefic (PK) tesfing (years 1 and 2, using cores B and C, M. Boska and C. Fletcher) in infected animals as a first pass screen for antiretroviral efficacy and tissue toxicities in vivo (oversight and biostafisfician support through core A, H. Gendelman). We will then proceed in specific aim 2 for PK, drug tissue distribufion, and safety studies in uninfected nonhuman primates (year 3), and then in specific aim 3 perform nanoART evaluafions in SHIV-infected monkeys, including PK, imaging, and efficacy studies, with extensive tissue analyses (years 3-5). These studies will predict whether long-spaced dosing protocols would yield acceptable drug plasma levels in monkeys and whether such developed protocols are efficacious against virus in primates. In toto, studies in the SHIV/rhesus monkey model will yield important information immediately applicable to future human clinical trials. The wealth of data, from pharmacokinefics, organ distribufion, effects on the virus, immune and other physiological systems are crucial pre-clinical steps in the development ofthis excifing therapeufic development.

Public Health Relevance

In the United States and in resource-limited setfings, HIV-1 infecfion remains a serious problem, contributing to morbidity and mortality of people often in the prime of life. One major difficulty and impediment to maintaining health is the frequent and regular dosing of medicafions;this is especially problemafic in those who are substance abusers. The strategies to be tested here are designed to address this impediment leading to improved health of these individuals as well as lowering potenfial transmission of HIV to others

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-AARR-D)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
United States
Zip Code
Olson, Katherine E; Gendelman, Howard E (2016) Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease. Curr Opin Pharmacol 26:87-95
Olson, Katherine E; Bade, Aditya N; Schutt, Charles R et al. (2016) Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. Neurotherapeutics 13:635-46
Ivanisevic, Julijana; Stauch, Kelly L; Petrascheck, Michael et al. (2016) Metabolic drift in the aging brain. Aging (Albany NY) 8:1000-20
Li, Weizhe; Tong, Hsin-I; Gorantla, Santhi et al. (2016) Neuropharmacologic Approaches to Restore the Brain's Microenvironment. J Neuroimmune Pharmacol 11:484-94
Singh, Dhirender; McMillan, JoEllyn; Hilaire, James et al. (2016) Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine (Lond) 11:1913-27
Sajja, Balasrinivasa R; Bade, Aditya N; Zhou, Biyun et al. (2016) Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγc(null) Mouse Brain Atlas. J Neuroimmune Pharmacol 11:133-41
Bade, Aditya N; Gorantla, Santhi; Dash, Prasanta K et al. (2016) Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice. Mol Neurobiol 53:3286-97
Zhang, Gang; Guo, Dongwei; Dash, Prasanta K et al. (2016) The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine 12:109-22
Dong, Weiguo; Embury, Christine M; Lu, Yaman et al. (2016) The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation. J Neuroinflammation 13:184
Guo, Dongwei; Zhou, Tian; Araínga, Mariluz et al. (2016) Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. J Acquir Immune Defic Syndr :

Showing the most recent 10 out of 103 publications